The ALIOF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ALIOF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ALIOF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ALIOF Detailed Price Forecast - CNN Money||View ALIOF Detailed Summary - Google Finance|
|View ALIOF Detailed Summary - Yahoo! Finance||View ALIOF Stock Research & Analysis - Zacks.com|
|View ALIOF Trends & Analysis - Trade-Ideas||View ALIOF Major Holders - Barrons|
|View ALIOF Call Transcripts - NASDAQ||View ALIOF Breaking News & Analysis - Seeking Alpha|
|View ALIOF Annual Report - CompanySpotlight.com||View ALIOF OTC Short Report - OTCShortReport.com|
|View ALIOF Fundamentals - TradeKing||View ALIOF SEC Filings - Bar Chart|
|View Historical Prices for ALIOF - The WSJ||View Performance/Total Return for ALIOF - Morningstar|
|View the Analyst Estimates for ALIOF - MarketWatch||View the Earnings History for ALIOF - CNBC|
|View the ALIOF Earnings - StockMarketWatch||View ALIOF Buy or Sell Recommendations - MacroAxis|
|View the ALIOF Bullish Patterns - American Bulls||View ALIOF Short Pain Metrics - ShortPainBot.com|
|View ALIOF Stock Mentions - StockTwits||View ALIOF Stock Mentions - PennyStockTweets|
|View ALIOF Stock Mentions - Twitter||View ALIOF Investment Forum News - Investor Hub|
|View ALIOF Stock Mentions - Yahoo! Message Board||View ALIOF Stock Mentions - Seeking Alpha|
|View Insider Transactions for ALIOF - SECform4.com||View Insider Transactions for ALIOF - Insider Cow|
|View ALIOF Major Holdings Summary - CNBC||View Insider Disclosure for ALIOF - OTC Markets|
|View Insider Transactions for ALIOF - Yahoo! Finance||View Institutional Holdings for ALIOF - NASDAQ|
|View ALIOF Stock Insight & Charts - FinViz.com||View ALIOF Investment Charts - StockCharts.com|
|View ALIOF Stock Overview & Charts - BarChart||View ALIOF User Generated Charts - Trading View|
Why 2017 Was a Year to Remember for Johnson & Johnson
Posted on Tuesday December 19, 2017
Three keys behind the healthcare giant's tremendous year in 2017 that could be critical for next year also.
Idorsia to get $230 million from J&J in latest hypertension deal
Posted on Sunday December 03, 2017
Idorsia (IDIA.S), the Swiss drugmaker spun off from Actelion after it was bought by Johnson & Johnson (J&J) (JNJ.N), will receive a one-time payment of $230 million (171 million pounds)from J&J's Janssen unit as they partner on aprocitentan for resistant hypertension. Aprocitentan is a metabolite of Actelion's Opsumit. Idorsia and J&J are seeking to develop it to treat hypertension patients whose disease has failed at least three therapies.
Idorsia to get $230 mln from J&J in latest hypertension deal
Posted on Sunday December 03, 2017
Idorsia, the Swiss drugmaker spun off from Actelion after it was bought by Johnson & Johnson (J&J), will receive a one-time payment of $230 million from J&J's Janssen unit as they partner on aprocitentan for resistant hypertension. Aprocitentan is a metabolite of Actelion's Opsumit. Idorsia and J&J are seeking to develop it to treat hypertension patients whose disease has failed at least three therapies.
Genmab and J&J 'love' partnership as some ponder takeover
Posted on Thursday November 30, 2017
Genmab was Europe's second biggest biotech company, until its partner Johnson & Johnson bought Switzerland's Actelion for $30 billion (£22.30 billion) this year and propelled the Danish antibody specialist to the top spot. Now some investors wonder if the same fate might await Genmab, worth $12 billion, given the soaraway success of its blood cancer drug Darzalex. J&J sells the drug and pays Genmab a royalty of 12 to 20 percent.